Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France-Reference-Cited by-同舟云学术

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Published:2021-09 Issue: Volume:8 Page:100171
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Charmet Tiffany,Schaeffer Laura,Grant Rebecca^ORCID,Galmiche Simon,Chény Olivia,Von Platen Cassandre,Maurizot Alexandra,Rogoff Alexandra,Omar Faïza,David Christophe,Septfons Alexandra,Cauchemez Simon,Gaymard Alexandre^ORCID,Lina Bruno,Lefrancois Louise H,Enouf Vincent,van der Werf Sylvie,Mailles Alexandra,Levy-Bruhl Daniel,Carrat Fabrice,Fontanet Arnaud

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference39 articles.

1. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England;Volz;Nature,2021

2. Detection of a SARS-CoV-2 variant of concern in South Africa;Tegally;Nature,2021

3. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil;Faria;Science,2021

4. Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19;Betton;Clin Infect Dis Off Publ Infect Dis Soc Am,2021

5. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma;Cele;Nature,2021

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Source of SARS-CoV-2 infection: results from a series of 584,846 cases in France from October 2020 to August 2022;BMC Public Health;2024-01-30

2. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice;Vaccines;2024-01-07

3. Comparative Pharmacological Efficacy of COVID-19 Vaccines against the Variants of Concerns (VOCs) of SARS-CoV-2: Recent Clinical Studies on Booster Dose;Current Pharmaceutical Biotechnology;2023-11

4. Source of SARS-CoV-2 infection: results from a series of 584,846 cases in France from October 2020 to August 2022;2023-10-28

5. SARS‐CoV‐2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy;CPT: Pharmacometrics & Systems Pharmacology;2023-08-21